Compare Mesoblast Limited (MESO) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs First Trust Cloud Computing ETF — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while First Trust Cloud Computing ETF trades at $135.94. The key difference: First Trust Cloud Computing ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | SKYY | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | — |
52-Week High | $20.96 | $155.17 |
52-Week Low | $12.88 | $104.16 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
First Trust Cloud Computing ETF (SKYY) trades at $136.66, up 0.41% with a bullish technical signal from moving averages. The ETF provides diversified exposure to cloud computing companies amid strong sector inflows driven by enterprise AI adoption. Recent news highlights continued institutional interest in technology ETFs, with SKYY positioned as a core holding for cloud computing exposure.
The outlook remains positive as cloud computing benefits from enterprise digital transformation and AI spending acceleration. Key risks include technology sector volatility and competitive pressures from alternative cloud ETFs. Analyst coverage emphasizes SKYY's established track record since 2011 launch and broad market positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
